Financial Performance - The company's revenue for Q1 2022 reached ¥8,841,150,250.19, representing a 125.16% increase compared to ¥3,926,600,928.88 in the same period last year[1] - Net profit attributable to shareholders was ¥1,922,756,886.80, up 104.95% from ¥938,179,113.58 year-on-year[1] - Operating costs for Q1 2022 were ¥6,503,327,142.16, up from ¥2,756,078,603.71 in the same period last year, indicating an increase of about 136.5%[16] - Net profit for Q1 2022 was ¥1,922,756,886.80, compared to ¥938,179,113.58 in Q1 2021, reflecting a growth of approximately 104.3%[18] - The net profit margin for Q1 2022 was approximately 21.7%, compared to 23.9% in Q1 2021, indicating a slight decline in profitability[19] - Basic and diluted earnings per share for Q1 2022 were both ¥1.2017, up from ¥0.5864 in Q1 2021, reflecting an increase of approximately 104.3%[19] Cash Flow - The net cash flow from operating activities was -¥3,316,743,954.40, a significant decline of 2,814.44% compared to -¥113,803,717.67 in the previous year[1] - Total cash inflow from operating activities is 5,120,358,696.65 CNY, up from 2,651,288,724.02 CNY in the previous period[21] - Cash outflow from operating activities totals 8,437,102,651.05 CNY, compared to 2,765,092,441.69 CNY in the previous period, reflecting increased operational costs[21] - The net cash flow from financing activities increased by 169.74% to ¥1,412,329,711.67, attributed to a reduction in repayments of short-term loans[8] - Cash flow from financing activities shows a net inflow of 1,412,329,711.67 CNY, a substantial increase from 523,588,052.11 CNY in the previous period[21] - The company paid 1,199,335,368.80 CNY in taxes during the current period, significantly higher than 440,557,817.58 CNY in the previous period[21] - Cash and cash equivalents at the end of the period amount to 1,961,452,199.09 CNY, compared to 1,304,768,272.67 CNY at the end of the previous period[21] Assets and Liabilities - Total assets increased by 3.94% to ¥31,232,017,191.18 from ¥30,047,323,465.36 at the end of the previous year[2] - The company's total liabilities decreased to ¥11,652,047,392.55 at the end of Q1 2022 from ¥12,390,110,553.53 at the beginning of the year, a reduction of approximately 5.9%[16] - The company's equity attributable to shareholders rose by 10.89% to ¥19,579,969,798.63 from ¥17,657,212,911.83[2] - The total current assets increased to 25,573,666,529.61 from 24,753,780,404.17, indicating a growth in liquidity[14] Accounts Receivable and Inventory - The company reported a significant increase in accounts receivable by 30.41% to ¥16,781,140,653.65, driven by sustained sales growth[5] - The accounts receivable rose to 16,781,140,653.65 from 12,867,543,957.77, reflecting an increase in sales or credit extended to customers[14] - The inventory decreased to 6,624,995,699.96 from 7,385,396,274.99, suggesting improved inventory management or reduced production[14] Research and Development - Research and development expenses surged by 161.12% to ¥160,890,893.91, reflecting increased investment in R&D projects[7] - Research and development expenses for Q1 2022 amounted to ¥160,890,893.91, significantly higher than ¥61,614,846.81 in Q1 2021, representing an increase of about 160.5%[18] Shareholder Information - As of the end of the reporting period, the total number of common shareholders was 89,963, with the top ten shareholders holding significant stakes, including Jiang Rensheng at 48.32%[9] - The total number of shares held by the top ten unrestricted shareholders includes Jiang Rensheng with 171,677,250 shares, indicating strong insider ownership[10] Product Issuance and Collaborations - The company reported a significant increase in the issuance of its products in Q1 2022, with the four-valent HPV vaccine issuance up by nearly 70% to 2.11 million doses, and the nine-valent HPV vaccine issuance up by 280% to 4.83 million doses[12] - The company continues its collaboration with Merck, focusing on increasing product supply to cover more eligible populations[12] Financial Management - The company is actively managing its financial assets, with a notable amount of 239,000,000 in other equity investments[14] - The company invested 409,610,155.15 CNY in fixed assets and intangible assets, down from 488,586,891.27 CNY in the previous period[21] - The company received 1,691,545,450.00 CNY in borrowings, slightly up from 1,593,398,716.00 CNY in the previous period[21] Exchange Rate Impact - The impact of exchange rate changes on cash and cash equivalents was -4,224,148.33 CNY, compared to a positive impact of 182,292.02 CNY in the previous period[21] Employee Engagement - The company has implemented an employee stock ownership plan, which was approved in early 2022, to enhance employee engagement and retention[11]

Financial Performance - The company's operating revenue for 2021 was CNY 30,652,415,906.61, representing a 101.79% increase compared to CNY 15,190,366,231.21 in 2020[13]. - The net profit attributable to shareholders for 2021 was CNY 10,208,548,452.56, a 209.23% increase from CNY 3,301,326,830.15 in 2020[13]. - The basic earnings per share for 2021 was CNY 6.3803, up 209.23% from CNY 2.0633 in 2020[13]. - The total assets at the end of 2021 amounted to CNY 30,047,323,465.36, a 97.48% increase from CNY 15,215,241,753.29 at the end of 2020[13]. - The company reported a weighted average return on equity of 78.01% for 2021, an increase of 31.72% compared to 46.29% in 2020[13]. - The total revenue for 2021 reached approximately CNY 30.65 billion, representing a year-on-year increase of 101.79% from CNY 15.19 billion in 2020[56]. - Revenue from self-developed products amounted to CNY 9.70 billion, accounting for 31.64% of total revenue, with a remarkable growth of 707.61% compared to CNY 1.20 billion in 2020[56]. - The company reported a significant increase in sales volume, reaching 284,180,087 doses in 2021, up 864.95% from 29,450,087 doses in 2020[59]. - The company achieved a revenue of CNY 30,652,415,906.61 in 2021, representing a growth of 101.79% compared to the previous year[29]. Dividend Distribution - The company plans to distribute a cash dividend of 6.00 CNY per 10 shares to all shareholders, based on a total of 1,600,000,000 shares[2]. - The company implemented a cash dividend policy, distributing 6.00 CNY per 10 shares, totaling 960 million CNY in cash dividends, which accounted for 100% of the total profit distribution[137]. - The company reported a total distributable profit of 12,291,924,179.08 CNY for the year 2021[137]. Research and Development - The company invested CNY 814 million in research and development during the reporting period[31]. - The company is investing heavily in R&D, with a budget allocation of 200 million RMB for the development of new vaccines and biopharmaceuticals[111]. - The company aims to enhance its vaccine research and development technology platform, targeting market potential and commercial development prospects[80]. - The company has multiple products in clinical trials, including three entering Phase III trials and two entering Phase I trials[30]. - The company has established three major R&D and production bases to accelerate the development and registration of high-quality products[42]. - The company has a strong pipeline of vaccines, including several in advanced clinical trial stages for various infectious diseases[32]. - The company has 11 products on the market, including vaccines for meningitis, cervical cancer, pneumonia, and rotavirus, addressing various infectious diseases[24]. Market Strategy and Operations - The company emphasizes a dual-driven development model of "technology + market" to support its growth strategy[23]. - The company operates under a "sales-driven production" model, aligning production with market demand[28]. - The company has established a professional marketing team of nearly 3,000 members, covering all 31 provinces and municipalities in China, and over 30,000 grassroots health service points[49]. - The company has a sales team of 2,817 members, which supports its operational plans but also presents management challenges[87]. - The company is actively pursuing WHO certification for its COVID-19 vaccine to improve accessibility and affordability, contributing to global immunization efforts[38]. - The company is focused on enhancing its brand influence and product competitiveness both domestically and internationally[85]. Compliance and Governance - The company emphasizes compliance and quality management, adhering to various laws and regulations to ensure sustainable operations[37]. - The company has a robust governance structure, with independent operational capabilities and no competition with its controlling shareholder[103]. - The company maintains independence from its controlling shareholder in terms of assets, personnel, finance, and operations[100]. - The company has established a performance evaluation and incentive mechanism that aligns with its development status[97]. - The company published 4 periodic reports and 64 temporary reports during the reporting period, enhancing information transparency[97]. Environmental Compliance - The company is classified as a key pollutant discharge unit, indicating compliance with environmental regulations[148]. - The total chemical oxygen demand (COD) discharge was 7.7896 tons, with a concentration of 56.0 mg/L, well below the permitted limit[148]. - The company has implemented measures to ensure no significant defects in non-financial reporting[147]. - The company reported a significant reduction in emissions, with sulfur dioxide levels at <3 mg/Nm³ and nitrogen oxides at 28 mg/Nm³, adhering to the relevant environmental standards[151]. - The company has completed the low-nitrogen combustion transformation of two boilers, further reducing nitrogen oxide emissions[154]. Shareholder Information - The total shares held by the board members at the beginning of the period were 904,121,300, with a decrease of 4,691,000 shares during the period, resulting in an ending total of 899,430,300 shares[106]. - The largest shareholder, Jiang Rensheng, holds 50.11% of the shares, totaling 801,829,000, with a decrease of 3,691,000 shares during the reporting period[183]. - The number of shareholders holding ordinary shares at the end of the reporting period was 111,593, an increase from 89,963 at the end of the previous month[183]. - The company introduced strategic investors through share transfers to optimize its equity structure and reduce operational risks[180]. Employee Engagement and Development - The company emphasizes employee training and development, focusing on various training programs to enhance employee capabilities and align with business goals[133]. - The employee stock ownership plan involved 761 core employees holding a total of 16,150,000 shares, representing approximately 1.01% of the company's total equity[138]. - The company has a diverse workforce, with 1,137 production staff, 2,817 sales personnel, and 566 technical staff[131]. - The company has a total of 491 employees with master's degrees and 6 with doctoral degrees, indicating a strong educational background among its workforce[131]. Future Outlook - The company plans to expand its production capacity by 40% in the next two years to meet growing demand for its vaccines[158]. - The company aims to achieve carbon neutrality by 2030, implementing various green initiatives across its operations[159]. - The company is exploring potential acquisitions to enhance its product portfolio, with a focus on companies specializing in innovative biotechnologies[111]. - Future outlook includes plans to expand into international markets, targeting a 15% increase in overseas sales by the end of the next fiscal year[111].